Meta-analysis assessing the impact of prior heart failure and chronic kidney disease on the cardiovascular efficacy of glucagon-like peptide-1 receptor agonists

GLP-1RAs seem to constitute a safe and efficacious treatment option in patients with T2DM and established or at high risk for atherosclerotic cardiovascular disease, while HF or CKD status at baseline do not substantially affect the observed cardio-protective effect against hard cardiovascular endpoints.